Stock Ratings / Health Care / INMD / financials

CBLL (45) CNMD (62) CV (44) TMDX (69) ⌘ Pro Terminal →

InMode Ltd. (INMD) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InMode Ltd. (NASDAQ: INMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $13.51 (+1.05% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #57 in composite RQD confidence.

Q: How does INMD compare to CBLL and CNMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for INMD?

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.51 (+1.05% on volume of 370,624 shares), positioning the stock -6.05% below its 50-day simple moving average ($14.38) and -5.72% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 20.0% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±3.2% ($13.08 to $13.94).

Q: How profitable is InMode Ltd. (INMD)?

In FY 2025 (10-K), INMD converted $370.5M of revenue into a 78.5% gross margin, 23% operating margin, and $84.3M in free cash flow (22.7% FCF margin).

$13.51 +1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.57

InMode Ltd. (INMD) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (79% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate) →

ROARABLE B • BUY Cap $776.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.57 (+0.43%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 22.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY • 69.4% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B- · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMD)Realized 20D OHLCV Swing Band: ±3.2%

Deterministic 5-Pillar Attribution (74/100 Composite)

🔍 WHY INMD SCORES 74/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 9.20 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (22% of score)

FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 24.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A$14.21-0.4% Next Q

Q2 (-2Q)

Grade A-$14.16-1.3% Next Q

Q3 (-1Q)

Grade B+$13.97-3.3% Next Q

Current

Grade B$13.51+7.3% Hist 90D α

Trajectory: A (82) → B (74)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 74/100 (B) score, INMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 76.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.38) or 200D SMA ($14.33) invalidates the momentum regime and cuts Target Base ($14.48) toward Bear Floor ($11.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 74%NO 26%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How INMD Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$84.3M (22.7% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $492.0M

FY24

Rev $394.8M

FY25

Rev $370.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$370.5M	78.5%	23%	$0	$84.3M	17.7%
FY 2024	$394.8M	80.3%	28.5%	$0	$132.0M	16.2%
FY 2023	$492.0M	78.5%	39.8%	$197.9M	$176.8M	17.7%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INMD)

✓Walkthrough of INMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.63%▼ SUPPORT BREAKDOWN

2026-10-30O $13.60H $13.60L $13.19C $13.51VOL 439.8K

RES: $14.58SUP: $14.00SMA50: $14.38SMA200: $14.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMD Butterfly Map → + Track INMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-8.3%/yr Implied 5Y Growth

vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMD)

Health Care Rank #57 of 1016 ⚔️ CBLL vs INMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMD vs. CBLL, CNMD, CV, TMDX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InMode Ltd. (INMD) ranks #57 by composite RQD confidence (74/100, grade B) and #390 by equity capitalization ($776.6M). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. INMD currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INMD ACTIVE InMode Ltd.	B	74/100	—	78.5%	17.7%	+1.05%	$776.6M	Benchmark Subject
CBLL CeriBell Inc.	D	45/100	—	87.9%	-35.0%	+2.20%	$1.07B	/cbll-vs-inmd →
CNMD CONMED Corporation	C	62/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-inmd →
CV CapsoVision Inc.	D	44/100	—	52.9%	-35.0%	-1.70%	$369.2M	/cv-vs-inmd →
TMDX TransMedics Group Inc.	C+	69/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-inmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001742692

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InMode Ltd. (INMD) reported GAAP revenue of $370.5M (-6.2% vs. FY2024 revenue of $394.8M , and -24.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $85.3M, and free cash flow of $84.3M (-36.1% YoY). On the balance sheet, INMD closed FY2025 with $766.4M in total assets against $0 in total debt (Altman Z-Score: 9.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$370.5M	$0	$85.3M	$84.3M	$766.4M	—
FY2024 (FY)	2024-12-31	$394.8M	$0	$132.7M	$132.0M	$785.7M	—
FY2023 (FY)	2023-12-31	$492.0M	$197.9M	$176.8M	$176.8M	—	—

3. INMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, InMode Ltd. (NASDAQ: INMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $13.51 (+1.05% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #57 in composite RQD confidence.

How does INMD compare to CBLL and CNMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INMD?

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.51 (+1.05% on volume of 370,624 shares), positioning the stock -6.05% below its 50-day simple moving average ($14.38) and -5.72% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 20.0% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±3.2% ($13.08 to $13.94).

INMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is InMode Ltd. (INMD)?

In FY 2025 (10-K), INMD converted $370.5M of revenue into a 78.5% gross margin, 23% operating margin, and $84.3M in free cash flow (22.7% FCF margin).

Direct Sub-Reports: INMD RQD Cockpit INMD 12M Forecast INMD Earnings & Move INMD Dividends & DRIP INMD Insiders & 13F INMD Whale Options INMD Profit Sankey INMD News & Why